{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T14:15:45Z","timestamp":1794665745495,"version":"4.9.1"},"reference-count":194,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2010,5,25]],"date-time":"2010-05-25T00:00:00Z","timestamp":1274745600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ther Apher Dial"],"published-print":{"date-parts":[[2010,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The Japanese Society for Dialysis Therapy (JSDT) guideline committee, chaired by Dr Y. Tsubakihara, presents the Japanese guidelines entitled \u201cGuidelines for Renal Anemia in Chronic Kidney Disease.\u201d These guidelines replace the \u201c2004 JSDT Guidelines for Renal Anemia in Chronic Hemodialysis Patients,\u201d and contain new, additional guidelines for peritoneal dialysis (PD), non\u2010dialysis (ND), and pediatric chronic kidney disease (CKD) patients.<\/jats:p><jats:p> <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"#ss3\">Chapter 1<\/jats:ext-link> presents reference values for diagnosing anemia that are based on the most recent epidemiological data from the general Japanese population. In both men and women, hemoglobin (Hb) levels decrease along with an increase in age and the level for diagnosing anemia has been set at &lt;13.5\u2003g\/dL in males and &lt;11.5\u2003g\/dL in females. However, the guidelines explicitly state that the target Hb level in erythropoiesis stimulating agent (ESA) therapy is different to the anemia reference level. In addition, in defining renal anemia, the guidelines emphasize that the reduced production of erythropoietin (EPO) that is associated with renal disorders is the primary cause of renal anemia, and that renal anemia refers to a condition in which there is no increased production of EPO and serum EPO levels remain within the reference range for healthy individuals without anemia, irrespective of the glomerular filtration rate (GFR). In other words, renal anemia is clearly identified as an \u201cendocrine disease.\u201d It is believed that defining renal anemia in this way will be extremely beneficial for ND patients exhibiting renal anemia despite having a high GFR. We have also emphasized that renal anemia may be treated not only with ESA therapy but also with appropriate iron supplementation and the improvement of anemia associated with chronic disease, which is associated with inflammation, and inadequate dialysis, another major cause of renal anemia.<\/jats:p><jats:p>In <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"#ss19\">Chapter 2<\/jats:ext-link>, which discusses the target Hb levels in ESA therapy, the guidelines establish different target levels for hemodialysis (HD) patients than for PD and ND patients, for two reasons: (i) In Japanese HD patients, Hb levels following hemodialysis rise considerably above their previous levels because of ultrafiltration\u2010induced hemoconcentration; and (ii) as noted in the 2004 guidelines, although 10 to 11\u2003g\/dL was optimal for long\u2010term prognosis if the Hb level prior to the hemodialysis session in an HD patient had been established at the target level, it has been reported that, based on data accumulated on Japanese PD and ND patients, in patients without serious cardiovascular disease, higher levels have a cardiac or renal function protective effect, without any safety issues. Accordingly, the guidelines establish a target Hb level in PD and ND patients of 11\u2003g\/dL or more, and recommend 13\u2003g\/dL as the criterion for dose reduction\/withdrawal. However, with the results of, for example, the CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) study in mind, the guidelines establish an upper limit of 12\u2003g\/dL for patients with serious cardiovascular disease or patients for whom the attending physician determines high Hb levels would not be appropriate.<\/jats:p><jats:p> <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"#ss26\">Chapter 3<\/jats:ext-link> discusses the criteria for iron supplementation. The guidelines establish reference levels for iron supplementation in Japan that are lower than those established in the Western guidelines. This is because of concerns about long\u2010term toxicity if the results of short\u2010term studies conducted by Western manufacturers, in which an ESA cost\u2010savings effect has been positioned as a primary endpoint, are too readily accepted. In other words, if the serum ferritin is &lt;100\u2003ng\/mL and the transferrin saturation rate (TSAT) is &lt;20%, then the criteria for iron supplementation will be met; if only one of these criteria is met, then iron supplementation should be considered unnecessary.<\/jats:p><jats:p>Although there is a dearth of supporting evidence for these criteria, there are patients that have been surviving on hemodialysis in Japan for more than 40\u2003years, and since there are approximately 20\u2003000 patients who have been receiving hemodialysis for more than 20\u2003years, which is a situation that is different from that in many other countries. As there are concerns about adverse reactions due to the overuse of iron preparations as well, we therefore adopted the expert opinion that evidence obtained from studies in which an ESA cost\u2010savings effect had been positioned as the primary endpoint should not be accepted unquestioningly.<\/jats:p><jats:p>In <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"#ss39\">Chapter 4<\/jats:ext-link>, which discusses ESA dosing regimens, and <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"#ss48\">Chapter 5<\/jats:ext-link>, which discusses poor response to ESAs, we gave priority to the usual doses that are listed in the package inserts of the ESAs that can be used in Japan. However, if the maximum dose of darbepoetin alfa that can currently be used in HD and PD patients were to be used, then the majority of poor responders would be rescued.<\/jats:p><jats:p>Blood transfusions are discussed in <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"#ss59\">Chapter 6<\/jats:ext-link>. Blood transfusions are attributed to the difficulty of managing renal anemia not only in HD patients, but also in end\u2010stage ND patients who respond poorly to ESAs. It is believed that the number of patients requiring transfusions could be reduced further if there were novel long\u2010acting ESAs that could be used for ND patients.<\/jats:p><jats:p> <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"#ss68\">Chapter 7<\/jats:ext-link> discusses adverse reactions to ESA therapy. Of particular concern is the emergence and exacerbation of hypertension associated with rapid hematopoiesis due to ESA therapy.<\/jats:p><jats:p>The treatment of renal anemia in pediatric CKD patients is discussed in <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"#ss82\">Chapter 8<\/jats:ext-link>; it is fundamentally the same as that in adults.<\/jats:p>","DOI":"10.1111\/j.1744-9987.2010.00836.x","type":"journal-article","created":{"date-parts":[[2010,5,26]],"date-time":"2010-05-26T13:56:49Z","timestamp":1274882209000},"page":"240-275","source":"Crossref","is-referenced-by-count":204,"title":["2008 Japanese Society for Dialysis Therapy: Guidelines for Renal Anemia in Chronic Kidney Disease"],"prefix":"10.1111","volume":"14","author":[{"given":"Yoshiharu","family":"Tsubakihara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Nishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Akiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Hirakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunitoshi","family":"Iseki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Kuriyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Nakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoshi","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Babazono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Hiramatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyasu","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masami","family":"Bessho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadao","family":"Akizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,5,25]]},"reference":[{"key":"e_1_2_12_2_2","first-page":"2017","volume-title":"About Reference Ranges, Miwa's Hematology","author":"Watanabe K","year":"2006"},{"key":"e_1_2_12_3_2","first-page":"888","volume-title":"Chronological Scientific","year":"2001"},{"issue":"2","key":"e_1_2_12_4_2","first-page":"ii","article-title":"Revised European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure","volume":"19","year":"2004","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"e_1_2_12_5_2","first-page":"S9","article-title":"K\/DOQI clinical practice guidelines and clinical recommendations for Anemia in Chronic Kidney Disease","volume":"47","author":"K\/DOQI","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"e_1_2_12_6_2","doi-asserted-by":"publisher","DOI":"10.4009\/jsdt.37.1737"},{"key":"e_1_2_12_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfm316"},{"key":"e_1_2_12_8_2","first-page":"292","article-title":"Analysis of plasma erythropoietin concentration in pre\u2010dialysis renal anemia patients","volume":"49","author":"Tsubakihara Y","year":"2007","journal-title":"J Jpn Soc Nephrol"},{"key":"e_1_2_12_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(88)80156-2"},{"key":"e_1_2_12_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(88)80573-0"},{"key":"e_1_2_12_11_2","first-page":"449","article-title":"Erythropoietin and inhibitors of in vitro erythropoiesis in the development of anaemia in children with renal disease","volume":"105","author":"McGonigle RJS","year":"1985","journal-title":"J Lab Clin Med"},{"issue":"9","key":"e_1_2_12_12_2","first-page":"24","article-title":"European Best Practice Guidelines for Peritoneal Dialysis","volume":"20","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"e_1_2_12_13_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2006.03.076"},{"key":"e_1_2_12_14_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2007.06.008"},{"key":"e_1_2_12_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-139X.2005.18105.x"},{"key":"e_1_2_12_16_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2003.00064.x"},{"key":"e_1_2_12_17_2","volume-title":"An Overview of Dialysis Treatment in Japan (As of Dec. 31, 1997)","author":"Statistical Survey Committee of the Japanese Society for Dialysis Therapy","year":"1998"},{"key":"e_1_2_12_18_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2004.03.023"},{"key":"e_1_2_12_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa065485"},{"key":"e_1_2_12_20_2","volume-title":"An Overview of Dialysis Treatment in Japan (As of Dec. 31, 2005)","author":"Statistical Survey Committee of the Japanese Society for Dialysis Therapy","year":"2006"},{"key":"e_1_2_12_21_2","volume-title":"An Overview of Dialysis Treatment in Japan (As of Dec. 31, 2006)","author":"Statistical Survey Committee of the Japanese Society for Dialysis Therapy","year":"2007"},{"key":"e_1_2_12_22_2","first-page":"87","volume-title":"Study for the Guidelines of Rhuepo Treatment in Dialysis Patients. Grant for Scientific Research Expenses for Health and Welfare Programs; Funds for Comprehensive Research on Long Term Chronic Disease (Renal Failure)","author":"Hirasawa Y","year":"1991"},{"key":"e_1_2_12_23_2","doi-asserted-by":"publisher","DOI":"10.4009\/jsdt.41.251"},{"key":"e_1_2_12_24_2","doi-asserted-by":"publisher","DOI":"10.4009\/jsdt.36.1265"},{"key":"e_1_2_12_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/16.4.798"},{"key":"e_1_2_12_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-9987.2007.00474.x"},{"key":"e_1_2_12_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-9987.2007.00544.x"},{"issue":"2","key":"e_1_2_12_28_2","first-page":"ii151","article-title":"Administered intravenously (IV) at extended administration intervals successfully maintains target hemoglobin (Hb) levels in Japanese patients with CKD on dialysis previously treated with recombinant human erythropoietin (EPO)","volume":"1","author":"Suzuki M","year":"2008","journal-title":"Nephrol Dial Transplant Plus"},{"key":"e_1_2_12_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(00)70334-9"},{"key":"e_1_2_12_30_2","doi-asserted-by":"publisher","DOI":"10.1159\/000190270"},{"key":"e_1_2_12_31_2","first-page":"505","article-title":"The effect of a higher hematocrit by erythropoietin (epoetin beta) on cardiovascular function in predialysis chronic renal failure patients","volume":"54","author":"Tsubakihara Y","year":"2003","journal-title":"Kidney Dial"},{"key":"e_1_2_12_32_2","first-page":"203","article-title":"The effect of recombinant human erythropoietin therapy for quality of life in renal failure","volume":"55","author":"Ikeda S","year":"2003","journal-title":"Kidney Dial"},{"key":"e_1_2_12_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-9987.2007.00525.x"},{"key":"e_1_2_12_34_2","first-page":"759A","article-title":"Target level for hemoglobin correction by Darbepoetin Alfa (KRN321) for Peritoneal Dialysis (PD) patients in Japan","volume":"18","author":"Kubota M","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_12_35_2","first-page":"618A","article-title":"Effect of Darbepoetin Alfa (KRN321) subcutaneous treatment on hemoglobin levels, Health\u2010Related QOL (HRQOL) and left ventricular mass index (LVMI) in patients with chronic kidney disease (CKD) not on dialysis","volume":"17","author":"Hirakata H","year":"2006","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"e_1_2_12_36_2","first-page":"vi352","article-title":"Monthly subcutaneous treatment of Darbepoetin Alfa (KRN321) could maintain higher Hb safety and have beneficial effects on cardiac function of Japanese CKD patients not on dialysis","volume":"22","author":"Inaguma D","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"e_1_2_12_37_2","first-page":"762A","article-title":"Target level for hemoglobin correction by Darbepoetin Alfa (KRN321) for patients with Chronic Kidney Disease (CKD) not on dialysis in randomized controlled study; from the Viewpoint of the Efficacy","volume":"18","author":"Akizawa T","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_12_38_2","first-page":"765A","article-title":"Target level for hemoglobin correction by Darbepoetin Alfa (KRN321) for patients with Chronic Kidney Disease (CKD) not on dialysis in randomized controlled study: from the viewpoint of the safety","volume":"18","author":"Tsubakihara Y","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"e_1_2_12_39_2","first-page":"ii151","article-title":"C.E.R.A. Administered either subcutaneously (SC) or intravenously (IV) at extended intervals alleviates anemia in Japanese patients with chronic kidney disease (CKD) not on dialysis","volume":"1","author":"Tsubakihara Y","year":"2008","journal-title":"Nephrol Dial Transplant Plus"},{"key":"e_1_2_12_40_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199808273390903"},{"key":"e_1_2_12_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(01)70008-X"},{"key":"e_1_2_12_42_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062276"},{"key":"e_1_2_12_43_2","unstructured":"FDA.FDA ALART [11\/16\/2006 Updated 2\/16\/2007 and 3\/9\/2007]: information for healthcare professionals. Erythropoiesis Stimulating Agents (ESA) [Aranesp (darbepoetin) Epogen (epoetin alfa) and Procrit (epoetin alfa)]. [Accessed 1 Oct 2008.] Available from URL:http:\/\/www.fda.gov\/cder\/drug\/InfoSheets\/HCP\/RHE_HCP.htm"},{"key":"e_1_2_12_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60194-9"},{"key":"e_1_2_12_45_2","unstructured":"Division of Medical Imaging and Hematology Products and Office of Surveillance and Epidemiology (OSE) of the FDA.Reassessment of the Risks of Erythropoiesis\u2010Stimulating Agents (ESAs) Administered for the Treatment of Anemia associated with Chronic Renal Failure. [Accessed 11 Jun 2008.] Available from URL:http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/07\/briefing\/2007\u20104315b1\u201001\u2010FDA.pdf"},{"key":"e_1_2_12_46_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2008.295"},{"key":"e_1_2_12_47_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfg1084"},{"key":"e_1_2_12_48_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2006.11.032"},{"key":"e_1_2_12_49_2","volume-title":"Guidelines for the Prevention and Treatment of Iron Deficiency and Iron Deficiency Anemia","author":"The Japan Bioiron Society","year":"2004"},{"key":"e_1_2_12_50_2","first-page":"1000","volume-title":"Iron Deficiency Anemia, Miwa's Hematology","author":"Niitsu Y","year":"2006"},{"key":"e_1_2_12_51_2","first-page":"329","volume-title":"Dictionary of Blood Purification","author":"Ueda T","year":"1999"},{"key":"e_1_2_12_52_2","first-page":"87","volume-title":"Today's Pharmaceutical Information XII","author":"Akiba T","year":"1995"},{"key":"e_1_2_12_53_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/10.supp2.92"},{"key":"e_1_2_12_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/0272-6386(95)90151-5"},{"issue":"2","key":"e_1_2_12_55_2","first-page":"ii7","article-title":"Outcomes of anaemia management in renal insufficiency and cardiac disease","volume":"18","author":"Silverberg D","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"e_1_2_12_56_2","first-page":"915","article-title":"Limitation of rHuEPO treatment for target Hb in peritoneal dialysis patients","volume":"63","author":"Hiramatsu M","year":"2007","journal-title":"Kidney Dial"},{"key":"e_1_2_12_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2007.01.026"},{"key":"e_1_2_12_58_2","first-page":"1","article-title":"Management of iron deficiency in renal anemia: guidelines for the optimal therapeutic approach in erythropoietin\u2010treated patients","volume":"48","author":"Drueke TB","year":"1997","journal-title":"Clin Nephrol"},{"key":"e_1_2_12_59_2","doi-asserted-by":"publisher","DOI":"10.1159\/000186246"},{"key":"e_1_2_12_60_2","doi-asserted-by":"publisher","DOI":"10.4009\/jsdt1985.24.1125"},{"key":"e_1_2_12_61_2","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1681\/ASN.V7122654","article-title":"The evaluation of iron status in hemodialysis patients","volume":"7","author":"Fishbane S","year":"1996","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_12_62_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/4.10.883"},{"issue":"5","key":"e_1_2_12_63_2","first-page":"521","article-title":"Endocrine abnormalities in hemodialysis patients with iron overload: reversal with iron depletion","volume":"11","author":"El\u2010Reshaid K","year":"1995","journal-title":"Nutrition"},{"key":"e_1_2_12_64_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2006080856"},{"key":"e_1_2_12_65_2","volume-title":"Iron Agents for Intravenous Administration: Fesin","author":"Wellfied Co. Ltd","year":"2000"},{"key":"e_1_2_12_66_2","volume-title":"Iron Agents for Intravenous Administration: Atofen","author":"Kyowa Pharmaceutical Industry Co. Ltd","year":"2005"},{"key":"e_1_2_12_67_2","volume-title":"Iron Agents for Intravenous Administration: Ferricon","author":"Nippon Zoki Pharmaceutical Co. Ltd","year":"1999"},{"key":"e_1_2_12_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/0272-6386(95)90105-1"},{"key":"e_1_2_12_69_2","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1093\/oxfordjournals.ndt.a027459","article-title":"Regular, low\u2010dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients","volume":"11","author":"Taylor JE","year":"1996","journal-title":"Nephrol Dial Transplant"},{"key":"e_1_2_12_70_2","doi-asserted-by":"publisher","DOI":"10.1159\/000096174"},{"key":"e_1_2_12_71_2","doi-asserted-by":"publisher","DOI":"10.5414\/CNP59115"},{"key":"e_1_2_12_72_2","doi-asserted-by":"publisher","DOI":"10.1086\/382878"},{"key":"e_1_2_12_73_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfl789"},{"key":"e_1_2_12_74_2","unstructured":"Anonymous.Summary of PRCA case reports. [Accessed 31 October 2002.] Available from the URL:http:\/\/www.jnj.com\/news\/1111"},{"key":"e_1_2_12_75_2","volume-title":"The Soluble Non\u2010Ionic Iron Formulations: Ferromia Tablets, Fine Granules","author":"Eisai Co. Ltd","year":"1995"},{"key":"e_1_2_12_76_2","volume-title":"Sustained Release Preparation: Ferrum","author":"Nichi\u2010iko Pharmaceutical Co. Ltd","year":"2005"},{"key":"e_1_2_12_77_2","volume-title":"Sustained Release Preparation: Fero\u2010Gradumet","author":"Abbott Japan Co. Ltd","year":"2007"},{"key":"e_1_2_12_78_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(99)70184-8"},{"key":"e_1_2_12_79_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.ndt.a092122"},{"key":"e_1_2_12_80_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(96)90462-X"},{"key":"e_1_2_12_81_2","first-page":"47","article-title":"A comparative study on acute toxicity of intravenous iron agents in rats","volume":"46","author":"Akiba T","year":"2001","journal-title":"Med Pharmcacol"},{"key":"e_1_2_12_82_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1996.487"},{"key":"e_1_2_12_83_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.00758.x"},{"key":"e_1_2_12_84_2","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/jama.1980.03310040025019","article-title":"Hemosiderosis in hemodialysis patients. An autopsy study of 50 cases","volume":"244","author":"Ali M","year":"1980","journal-title":"JAMA"},{"key":"e_1_2_12_85_2","first-page":"369","article-title":"The role of iron deposition into bone calcification front in renal osteodystrophy","volume":"3","author":"Kurihara S","year":"1990","journal-title":"Kidney Bone Metab Dis"},{"key":"e_1_2_12_86_2","first-page":"377","article-title":"Risk factors for bacterial infections in chronic haemodialysis adult patients: a multicentre prospective survey","volume":"10","author":"Hoen B","year":"1995","journal-title":"Nephrol Dial Transplant"},{"key":"e_1_2_12_87_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2002.05701.x"},{"key":"e_1_2_12_88_2","doi-asserted-by":"publisher","DOI":"10.1159\/000419523"},{"key":"e_1_2_12_89_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(91)90120-M"},{"key":"e_1_2_12_90_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.ndt.a092082"},{"key":"e_1_2_12_91_2","doi-asserted-by":"publisher","DOI":"10.1159\/000168464"},{"key":"e_1_2_12_92_2","first-page":"297","article-title":"Erythropoietin response and route of administration","volume":"41","author":"Taylor JE","year":"1994","journal-title":"Clin Nephrol"},{"key":"e_1_2_12_93_2","doi-asserted-by":"publisher","DOI":"10.1016\/0272-6386(95)90654-1"},{"key":"e_1_2_12_94_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050088"},{"key":"e_1_2_12_95_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(96)90498-9"},{"key":"e_1_2_12_96_2","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1681\/ASN.V82288","article-title":"Safety and efficacy of low\u2010dose subcutaneous erythropoietin in hemodialysis patients","volume":"8","author":"Parker KP","year":"1997","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_12_97_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/13.7.1770"},{"key":"e_1_2_12_98_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199808273390902"},{"key":"e_1_2_12_99_2","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.2002.34881"},{"key":"e_1_2_12_100_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(01)01103-2"},{"issue":"5","key":"e_1_2_12_101_2","first-page":"S19","article-title":"Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure. Guideline 9. Route of administration of epoetin","volume":"14","author":"Working Party for European Best Practice","year":"1999","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"e_1_2_12_102_2","first-page":"S207","article-title":"Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000","volume":"37","author":"NKF\u2010K\/DOQI","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"e_1_2_12_103_2","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1182\/blood.V76.9.1718.1718","article-title":"Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers","volume":"76","author":"McMahon FG","year":"1990","journal-title":"Blood"},{"key":"e_1_2_12_104_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(99)70258-1"},{"key":"e_1_2_12_105_2","first-page":"195","article-title":"Double\u2010blind comparison of the effects of recombinant human erythropietin (SNB\u20105001) on renal anemia in hemodialysis patients between intravenous and subcutaneous administration","volume":"21","author":"Koshikawa S","year":"1993","journal-title":"Rinsyo Hyoka"},{"key":"e_1_2_12_106_2","doi-asserted-by":"publisher","DOI":"10.4009\/jsdt1985.26.479"},{"key":"e_1_2_12_107_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20245"},{"issue":"1","key":"e_1_2_12_108_2","first-page":"907","article-title":"A case of pure red blood cell aplasia due to anti\u2010EPO antibodies","volume":"37","author":"Sogabe A","year":"2004","journal-title":"J Jpn Soc Dial Ther"},{"key":"e_1_2_12_109_2","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1681\/ASN.V10112392","article-title":"Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients","volume":"10","author":"Macdougall IC","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_12_110_2","first-page":"505","article-title":"Current management of renal anemia in patients with chronic kidney disease at the predialysis stage","volume":"49","author":"Kuriyama S","year":"2007","journal-title":"J Jpn Soc Nephrol"},{"key":"e_1_2_12_111_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-111-12-992"},{"key":"e_1_2_12_112_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198701083160203"},{"key":"e_1_2_12_113_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/5.3.232"},{"key":"e_1_2_12_114_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/10.supp2.69"},{"key":"e_1_2_12_115_2","first-page":"462","article-title":"Impaired response to recombinant erythropoietin therapy in children with peritonitis","volume":"23","author":"Hymes LC","year":"1994","journal-title":"Dial Transplant"},{"key":"e_1_2_12_116_2","first-page":"270","article-title":"Increased erythropoietin requirements in patients with failed renal transplants returning to a dialysis programme","volume":"9","author":"Almond MK","year":"1994","journal-title":"Nephrol Dial Tranplant"},{"key":"e_1_2_12_117_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199301213280304"},{"key":"e_1_2_12_118_2","doi-asserted-by":"publisher","DOI":"10.1159\/000169979"},{"key":"e_1_2_12_119_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)90067-F"},{"key":"e_1_2_12_120_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/6.5.342"},{"key":"e_1_2_12_121_2","doi-asserted-by":"publisher","DOI":"10.1159\/000417908"},{"key":"e_1_2_12_122_2","doi-asserted-by":"publisher","DOI":"10.1159\/000168443"},{"key":"e_1_2_12_123_2","doi-asserted-by":"publisher","DOI":"10.1159\/000188758"},{"key":"e_1_2_12_124_2","first-page":"176","article-title":"Is erythropoietin treatment safe and effective in myeloma patients receiving hemodialysis?","volume":"40","author":"Caillette A","year":"1993","journal-title":"Clin Nephrol"},{"key":"e_1_2_12_125_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.301.6750.476"},{"key":"e_1_2_12_126_2","first-page":"29","article-title":"Use of recombinant human erythropoietin in the treatment of anemia in patients who have cancer","volume":"19","author":"Abels RI","year":"1992","journal-title":"Semin Oncol"},{"key":"e_1_2_12_127_2","doi-asserted-by":"publisher","DOI":"10.1159\/000188687"},{"key":"e_1_2_12_128_2","doi-asserted-by":"publisher","DOI":"10.1159\/000168605"},{"key":"e_1_2_12_129_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(13)80004-2"},{"key":"e_1_2_12_130_2","first-page":"817","article-title":"Effect of recombinant human erythropoietin on erythropoiesis in homozygous sickle\u2010cell anemia and renal failure","volume":"7","author":"Tomson CR","year":"1992","journal-title":"Nephrol Dial Tranplant"},{"key":"e_1_2_12_131_2","doi-asserted-by":"publisher","DOI":"10.1159\/000418719"},{"key":"e_1_2_12_132_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011931"},{"key":"e_1_2_12_133_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199602153340702"},{"key":"e_1_2_12_134_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-9987.2006.00388.x"},{"key":"e_1_2_12_135_2","first-page":"1456","article-title":"A population study of the interplay between iron, nutrition, and inflammation in erythropoiesis in hemodialysis patients","volume":"7","author":"Madour F","year":"1996","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_12_136_2","doi-asserted-by":"publisher","DOI":"10.1016\/0272-6386(95)90439-5"},{"key":"e_1_2_12_137_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/10.supp6.44"},{"key":"e_1_2_12_138_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/12.11.2312"},{"key":"e_1_2_12_139_2","first-page":"357A","article-title":"Oral zinc supplementation reduces mean erythropoietin (EPO) dose in EPO required hemodialysis patients","volume":"12","author":"Iwasaki S","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_12_140_2","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.45.1541"},{"key":"e_1_2_12_141_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.ndt.a027287"},{"key":"e_1_2_12_142_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000071514.36428.61"},{"key":"e_1_2_12_143_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh732"},{"key":"e_1_2_12_144_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20740"},{"key":"e_1_2_12_145_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/10.supp2.62"},{"key":"e_1_2_12_146_2","first-page":"105","article-title":"Erythropoietin resistance in patients on continuous ambulatory peritoneal dialysis","volume":"20","author":"Nakamoto H","year":"2004","journal-title":"Adv Perit Dial"},{"key":"e_1_2_12_147_2","first-page":"403","article-title":"Practice strategies for elective red blood cell transfusion","volume":"6","author":"Audet A\u2010M","year":"1992","journal-title":"Ann Intern Med"},{"key":"e_1_2_12_148_2","first-page":"977","article-title":"Dose\u2010evaluation study of intravenous darbepoetin alfa (KRN321) in EPO\u2010naive hemodialysis patients in Japan","volume":"62","author":"Naruse T","year":"2007","journal-title":"Kidney Dial"},{"key":"e_1_2_12_149_2","first-page":"349","article-title":"Dose\u2010finding and long\u2010term studies of intravenous KRN321 (darbepoetin alfa) in chronic renal failure patients on hemodialysis in Japan","volume":"62","author":"Kawanishi H","year":"2007","journal-title":"Kidney Dial"},{"key":"e_1_2_12_150_2","first-page":"679","article-title":"Randomized, controlled study of darbepoetin alfa for the treatment of anemia in hemodialysis patients","volume":"62","author":"Hori K","year":"2007","journal-title":"Kidney Dial"},{"key":"e_1_2_12_151_2","first-page":"335","article-title":"An open\u2010label study of the long\u2010term safety of KRN321 therapy in subjects with CRF receiving hemodialysis who were previously enrolled in dose\u2010finding study of KRN321","volume":"62","author":"Kawanishi H","year":"2007","journal-title":"Kidney Dial"},{"key":"e_1_2_12_152_2","first-page":"1139","article-title":"Erythropoietin treatment and hypertension. Hematological problems in dialysis treatment","volume":"14","author":"Kusano E","year":"1998","journal-title":"Rynsho Toseki"},{"key":"e_1_2_12_153_2","volume-title":"Long\u2010Lasting Erythropoiesis Stimulating Agent: Nesp","author":"Kirin Pharma Co. Ltd","year":"2007"},{"key":"e_1_2_12_154_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(93)90151-E"},{"key":"e_1_2_12_155_2","doi-asserted-by":"publisher","DOI":"10.1291\/hypres.24.501"},{"key":"e_1_2_12_156_2","doi-asserted-by":"publisher","DOI":"10.1159\/000188803"},{"key":"e_1_2_12_157_2","doi-asserted-by":"publisher","DOI":"10.1002\/1520-6017(200101)90:1<1::AID-JPS1>3.0.CO;2-K"},{"key":"e_1_2_12_158_2","unstructured":"Anonymous.Summary of PRCA case reports. [Accessed 31 October 2002.] Available from the URL:http:\/\/www.jnj.com\/news\/"},{"key":"e_1_2_12_159_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfl727"},{"key":"e_1_2_12_160_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfl331"},{"key":"e_1_2_12_161_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-003-1126-0"},{"key":"e_1_2_12_162_2","first-page":"1","article-title":"Hematological and iron\u2010related analyses? Reference data for persons aged 1\u2003years and over: United States, 1988\u201394. Centers for Disease Control and Prevention, National Center for Health Statistics","volume":"11","author":"Hollowell JG","year":"2005","journal-title":"Vital Health Stat"},{"key":"e_1_2_12_163_2","first-page":"1841","volume-title":"Hematology of Infancy and Childhood","author":"Nathan DG","year":"2003"},{"key":"e_1_2_12_164_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004670050584"},{"key":"e_1_2_12_165_2","first-page":"1111","volume-title":"Management of Anemia in Pediatric Patients, in Clinical Dialysis","author":"Greenbaum LA","year":"2005"},{"key":"e_1_2_12_166_2","first-page":"3251","article-title":"Clinical Results of Recombinant Human Erythropoietin (EPOCH) in pediatric renal anemia patients","volume":"41","author":"The Association of EPOCH Clinical Evaluation in Pediatric Patients","year":"1988","journal-title":"Jpn J Pediatr"},{"key":"e_1_2_12_167_2","first-page":"499","article-title":"Clinical Evaluation of Recombinant Human Erythropoietin (EPOCH) in pediatric renal anemia patients\u2014the effect on pre\u2010dialysis patients","volume":"43","author":"The Association of EPOCH Clinical Evaluation in Pediatric Patients","year":"1990","journal-title":"Jpn J Pediatr"},{"key":"e_1_2_12_168_2","first-page":"1461","article-title":"Evaluation of Subcutaneous Recombinant Human Erythropoietin (EPOCH) in pediatric renal anemia patients\u2014a study in pre\u2010dialysis and CAPD patients","volume":"47","author":"The Association of EPOCH Clinical Evaluation in Pediatric Patients","year":"1994","journal-title":"Jpn J Pediatr"},{"key":"e_1_2_12_169_2","first-page":"163","article-title":"The clinical effects of KRN5702 in pediatric renal anemia HD patients","volume":"45","author":"Kitagawa T","year":"1992","journal-title":"Jpn J Pediatr"},{"key":"e_1_2_12_170_2","first-page":"353","article-title":"The clinical effects of KRN5702 in pediatric renal anemia pre\u2010dialysis patients","volume":"45","author":"Ito K","year":"1992","journal-title":"Jpn J Pediatr"},{"key":"e_1_2_12_171_2","first-page":"1613","article-title":"A clinical investigation of subcutaneous KRN5702 in pediatric renal anemia pre\u2010dialysis patients","volume":"46","author":"Ito K","year":"1993","journal-title":"Jpn J Pediatr"},{"issue":"1","key":"e_1_2_12_172_2","first-page":"S153","article-title":"Pediatric ESRD in United States Renal Data System (USRDS) 2004. Annual report","volume":"45","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"e_1_2_12_173_2","first-page":"952","volume-title":"Anemia: General Considerations, Wintrobe.S Clinical Hematology","author":"Glader B","year":"2004"},{"key":"e_1_2_12_174_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-003-1214-1"},{"key":"e_1_2_12_175_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004670000303"},{"key":"e_1_2_12_176_2","first-page":"339A","article-title":"Anemia\u2010associated risk of disease progression in pediatric chronic kidney disease (CKD): an analysis of the NAPRTCS","volume":"17","author":"Staples A","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_12_177_2","doi-asserted-by":"publisher","DOI":"10.1136\/adc.69.5.580"},{"key":"e_1_2_12_178_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00860930"},{"key":"e_1_2_12_179_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2004.08.024"},{"key":"e_1_2_12_180_2","doi-asserted-by":"publisher","DOI":"10.1053\/snep.2001.24940"},{"key":"e_1_2_12_181_2","first-page":"481","article-title":"Hemolysis and blood loss in children with chronic renal failure","volume":"8","author":"Muller\u2010Wiefel DE","year":"1977","journal-title":"Clin Nephrol"},{"key":"e_1_2_12_182_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2004.00357.x"},{"key":"e_1_2_12_183_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-004-1421-4"},{"key":"e_1_2_12_184_2","doi-asserted-by":"publisher","DOI":"10.1097\/MCO.0b013e3280523aaf"},{"key":"e_1_2_12_185_2","volume-title":"North American Pediatric Renal Transplant Cooperative Study (NAPRTCS) 2004 Annual Report","author":"NAPRTCS Administrative Office","year":"2004"},{"key":"e_1_2_12_186_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-003-1364-1"},{"key":"e_1_2_12_187_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.00592.x"},{"key":"e_1_2_12_188_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-006-0071-0"},{"key":"e_1_2_12_189_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-006-0402-1"},{"key":"e_1_2_12_190_2","doi-asserted-by":"publisher","DOI":"10.1067\/mpd.2001.112246"},{"key":"e_1_2_12_191_2","first-page":"448","article-title":"Erythropoietin associated hypertension among pediatric dialysis patients","volume":"8","author":"Komatsu Y","year":"1992","journal-title":"Adv Perit Dial"},{"key":"e_1_2_12_192_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004670050583"},{"key":"e_1_2_12_193_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040528"},{"key":"e_1_2_12_194_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfm384"},{"key":"e_1_2_12_195_2","first-page":"99","article-title":"The second international reference preparation of erythropoietin, human, urinary, for bioassay","volume":"47","author":"Annabel L","year":"1972","journal-title":"Bull Wld Hlth Org"}],"container-title":["Therapeutic Apheresis and Dialysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1744-9987.2010.00836.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1744-9987.2010.00836.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T06:55:00Z","timestamp":1697266500000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1744-9987.2010.00836.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,25]]},"references-count":194,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["10.1111\/j.1744-9987.2010.00836.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1744-9987.2010.00836.x","archive":["Portico"],"relation":{},"ISSN":["1744-9979","1744-9987"],"issn-type":[{"value":"1744-9979","type":"print"},{"value":"1744-9987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5,25]]}}}